Genmab partner receives conditional EU approval for cancer drug

The EU Commission has followed the recommendation of its expert panel and has granted Janssen conditional marketing authorization of Genmab's Rybrevant (amivantamab) for the treatment of advanced non-small cell lung cancer.
Photo: Janssen/PR
Photo: Janssen/PR
by marketwire, translated by daniel pedersen

Genmab's US partner Janssen has received conditional marketing authorization for amivantamab, marketed as Rybrevant, by the EU Commission, Genmab announces in a press release on Monday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading